TSP Capital Management Group, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.

Quarter-by-quarter ownership
TSP Capital Management Group, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$6,926,645
-19.0%
251,695
-0.1%
2.67%
-13.4%
Q2 2023$8,546,800
-5.9%
251,895
-0.2%
3.08%
-6.0%
Q1 2023$9,081,173
-24.5%
252,395
-6.5%
3.28%
-27.1%
Q4 2022$12,029,225
+60.1%
269,895
+1.0%
4.50%
+42.0%
Q3 2022$7,514,000
+4.6%
267,295
+0.3%
3.17%
+12.0%
Q2 2022$7,186,000
-21.6%
266,545
-0.9%
2.83%
-8.6%
Q1 2022$9,164,000
-6.5%
269,045
+6.1%
3.10%
-5.5%
Q4 2021$9,803,000
-33.1%
253,696
-6.5%
3.27%
-34.6%
Q3 2021$14,654,000
+28.9%
271,429
-20.2%
5.00%
+33.9%
Q2 2021$11,367,000
+53.6%
339,929
-5.4%
3.74%
+43.2%
Q1 2021$7,400,000
+4.7%
359,229
-10.9%
2.61%
+3.9%
Q4 2020$7,065,000
+7.8%
403,229
-8.7%
2.51%
-6.3%
Q3 2020$6,551,000
+37.0%
441,729
+20.0%
2.68%
+31.2%
Q2 2020$4,783,000
+602.3%
367,961
-10.3%
2.04%
+430.6%
Q1 2020$681,000
-14.4%
410,017
+14.9%
0.38%
+13.6%
Q4 2019$796,000
+127.4%
356,890
+117.4%
0.34%
+93.7%
Q3 2019$350,000
-15.9%
164,142
+5.8%
0.18%
-9.3%
Q2 2019$416,000
-46.0%
155,081
-0.9%
0.19%
-49.6%
Q1 2019$770,000156,4140.38%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2021
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders